Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines
-
By
-
Chao-qun Zhou
-
Shi-Qiong Zhou
-
Qing-Hua Ke
-
May 26, 2026
-
Clinical Scorecard: Enhancing CAR-T Treatment for Multiple Myeloma: An In-Depth Review of CARTITUDE-4 and the Journey Towards Earlier Interventions
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | BCMA-directed CAR T-cell therapy (cilta-cel) as per CARTITUDE-4 trial findings. |
| Target Population | |
| Care Setting | |
Key Highlights
- CARTITUDE-4 trial shows significant overall survival (OS) benefit with cilta-cel (HR 0.55, p=0.0009) as per trial results.
- High rates of minimal residual disease negativity (62% at 10-5) observed in trial data.
Guideline-Based Recommendations
Diagnosis
- Consider cilta-cel for lenalidomide-refractory multiple myeloma after 1–3 prior lines as per guidelines.
Management
- Standardized bridging therapy should be prioritized in future protocols as per expert recommendations.
Monitoring & Follow-up
- Lifetime monitoring for secondary malignancies and toxicity assessment is necessary as per safety guidelines.
Risks
- Potential for secondary hematological malignancies and other long-term risks as noted in safety assessments.
Patient & Prescribing Data
Patients with lenalidomide-refractory multiple myeloma
Cilta-cel shows promise for earlier intervention in the treatment continuum
Clinical Best Practices
- Implement standardized bridging strategies to optimize treatment outcomes as per trial recommendations.
- Ensure informed consent includes discussion of long-term risks as per safety guidelines.
Related Resources & Content
